Immunovant is a startup. Brouky records 1 investor associated with the company.
Immunovant, Inc. is a clinical-stage biopharmaceutical company developing therapeutic candidates to treat autoimmune diseases with the goal of enabling normal lives for patients.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.